Low dose daily rhGM-CSF application activates monocytes and dendritic cells in vivo

Leuk Res. 2003 Dec;27(12):1105-8. doi: 10.1016/s0145-2126(03)00097-3.

Abstract

Granulocyte macrophage colony stimulating factor (GM-CSF) is a powerful cytokine with multiple actions. We investigated the effects of low dose daily rhGM-CSF application on monocytes and peripheral circulating dendritic cells (DC) in malignant melanoma patients in vivo. Twenty patients were included; rhGM-CSF was given as daily subcutaneous injections for 14 days. A significant increase was noted in monocytes and granulocytes, starting on the 5th day. Expression of CD95 (Apo-1/Fas) and CD45RO on monocytes increased significantly on the 5th day, and CD4 expression on monocytes increased significantly on the 14th day. Peripheral circulating dendritic cells which were 0.94% in the beginning, increased to 1.35% (P<0.04) and to 1.96% (P<0.001) on days 5 and 14, respectively.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Dendritic Cells / immunology*
  • Female
  • Flow Cytometry
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage*
  • Granulocytes
  • Humans
  • Injections, Subcutaneous
  • Leukocyte Common Antigens / metabolism
  • Male
  • Melanoma / immunology*
  • Middle Aged
  • Monocytes / immunology*
  • Neoplastic Cells, Circulating
  • Prospective Studies
  • Recombinant Proteins
  • fas Receptor / metabolism

Substances

  • Recombinant Proteins
  • fas Receptor
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Leukocyte Common Antigens